Skip to main content

Welcome to Janssen United States

VISIT JANSSEN GLOBAL

Press Releases

Aug 25, 2021

NEW BRUNSWICK, N.J.

Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine

Aug 24, 2021

RARITAN, NJ

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD

Aug 19, 2021

RARITAN, N.J.

Janssen Presents Phase 1 Results for RYBREVANT^TM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations

Jul 30, 2021

TITUSVILLE, N.J.

UPTRAVI® (selexipag) Receives FDA Approval for Intravenous Use in Adult Patients with Pulmonary Arterial Hypertension (PAH)

Jul 29, 2021

NEW BRUNSWICK, N.J.

Johnson & Johnson Statement on U.S. FDA Approval of Shelf Life Extension for Company’s COVID-19 Vaccine

Jul 14, 2021

NEW BRUNSWICK, N.J.

Johnson & Johnson Single-Shot COVID-19 Vaccine Demonstrated a Durable Immune Response and Elicited Dual Mechanisms of Protection Against Delta and Other SARS-CoV-2 Variants of Concern in Data Published in New England Journal of Medicine

Jul 13, 2021

NEW BRUNSWICK, N.J.

Johnson & Johnson Statement on COVID-19 Vaccine

Jul 12, 2021

HORSHAM, P.A.

Janssen Announces U.S. FDA Approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse

Jul 09, 2021

SPRING HOUSE, PENNSYLVANIA

STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial

Jul 01, 2021

NEW BRUNSWICK, N.J.

Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response